HCPCS Level II · Drugs administered other than oral method
J0221Injection, alglucosidase alfa, (lumizyme), 10 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0221
J0221 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, alglucosidase alfa, (lumizyme), 10 mg.
It was added to HCPCS effective 01/01/2012.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Lumizyme injection
- Date added
- 01/01/2012
- Action effective
- 01/01/2012
- BETOS
- O1E
Related J02xx codes
- J0202Injection, alemtuzumab, 1 mg
- J0206Injection, allopurinol sodium, 1 mg
- J0207Injection, amifostine, 500 mg
- J0208Injection, sodium thiosulfate (pedmark), 100 mg
- J0209Injection, sodium thiosulfate (hope), 100 mg
- J0210Injection, methyldopate hcl, up to 250 mg
- J0211Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
- J0216Injection, alfentanil hydrochloride, 500 micrograms
- J0217Injection, velmanase alfa-tycv, 1 mg
- J0218Injection, olipudase alfa-rpcp, 1 mg
- J0219Injection, avalglucosidase alfa-ngpt, 4 mg
- J0220Injection, alglucosidase alfa, 10 mg, not otherwise specified
Common questions about J0221
Is HCPCS J0221 still valid?
- Yes. J0221 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J0221?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.